Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Radiesse and Restylane Lyft are the only two fillers that are FDA-approved for use in the hands, says Dr. Fabi, adding that ...

Amazon has become the go-to online shopping mall for everything from dog food and doorknobs to bedding and bestsellers for ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...